The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...
This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn.Boehringer Ingelheim today announced that The New ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
The non-small cell lung cancer clinical trial analysis report delivers important insights into ongoing research of 120+ ...
First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...
There are many treatment options for lung cancer, but the right one for you will depend on many factors including the type of lung cancer you have. Non-small-cell lung cancer (NSCLC) is the most ...
The Business Research Company's Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Non-Small Cell Lung Cancer (NSCLC) Global Market ...
A joint research group consisting of Saitama Medical University and Meiji Holdings Co., Ltd. today announced results from a ...
Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above ...
You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical ...
Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results from the Phase 1b Beamion LUNG-1 trial of HERNEXEOS® (zongertinib tablets) in treatment-naïve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results